Last updated on August 2017

A Study of AbGn-107 in Patients With Gastric Colorectal or Pancreatic Cancer


Brief description of study

This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107 administered every 28 days (4 weeks) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal or pancreatic adenocarcinoma.

Detailed Study Description

AbGn-107 is an antibody drug conjugate (ADC) which targets an antigen (AG7 antigen) present in gastric, colorectal, and pancreatic cancer. This study is a standard 3 + 3 dose escalation design with cohort expansion. AbGn-107 will be administered every 28 days in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal or pancreatic adenocarcinoma. The primary objectives of this study are to define the safety profile and to determine the maximum tolerated dose (MTD), and the secondary objectives are to evaluate the pharmacokinetic (PK) parameters, the immunogenicity, and preliminary efficacy.

Clinical Study Identifier: NCT02908451

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Tanios S Bekaii-Saab, MD

Mayo Clinic
Phoenix, AZ United States
  Connect »

Andrew Ko, MD

University of California
San Francisco, CA United States
  Connect »

Jeffrey Clark, MD

Massachusetts General Hospital
Boston, MA United States
  Connect »

Benjamin Schlechter, MD

Beth-Israel Deaconess Medical Center
Boston, MA United States
  Connect »

Brian M Wolpin, MD

Dana-Farber Cancer Institute
Boston, MA United States
  Connect »

Andrew Coveler, MD

University of Washington, Seattle Cancer Care Alliance
Seattle, WA United States
  Connect »